Secretary Azar's drug price plan will undermine access to life-changing medicines here in the United States.
Secretary Azar’s drug price plan will undermine access to life-changing medicines here in the United States.

HHS Secretary Azar’s drug price plan is a gift to global “freeloaders”

By Peter J. Pitts

Prescription drugs are costly in the United States. In an effort to lower the prices Americans pay at the pharmacy, President Trump pledged to end “the global freeloading that forces American consumers to subsidize lower prices in foreign countries.”

Unfortunately, a new plan from the Department of Health and Human Services undermines this goal.

Health and Human Services Sec. Alex Azar unveiled a new Medicare proposal that simply copies the foreign price-control policies that have enabled other countries to underpay for drugs. Not only does the change fail to hold “freeloading” countries accountable, it will undermine access to life-changing medicines here in the United States.

Why are brand-name drugs cheaper in foreign countries? Simply put, it’s because of price controls. In countries like the United Kingdom, Canada, and Sweden, the government dictates what drug companies can charge for their products.

The prices of prescription drugs sold in Sweden, for instance, are determined by the Pharmaceutical Benefits Board. Canada’s Patented Medicine Prices Review Board plays a similar role.

The single-payer healthcare systems in these countries are what make such price controls possible. When the government is the sole administrator of prescription drugs, it has extraordinary bargaining power to secure below-market prices.

American patients pick up the tab by shouldering much of the burden for global research and development. This is unfair and something that President Trump is right to condemn.

HHS’ new Medicare proposal does little to rectify the situation. The policy would change what the government pays for drugs under Medicare Part B, a part of the program that covers medicines administered at a doctor’s office, such as cancer therapies.

Under HHS’ plan, Part B would base its drug payments not on a drug’s average domestic price, as the program does now, but on what other countries pay for the same medicine.

Patients often lose access to the best medicines when their government adopts price controls. Of the drugs launched since 2011, only 60 percent were available in Sweden. And only half made it to patients in Canada.

In the United States, meanwhile, nearly 90 of those medicines were available. Americans will no longer enjoy generous access to the newest drugs if we embrace price controls.

It costs an estimated $2.6 billion to create a single new medicine. That investment is only worthwhile if drug companies are confident that they’ll have a chance to recoup their upfront costs.

Importing the socialist pricing tactics of foreign governments is no way to stand up for Medicare patients. The Trump administration should explore policies that ensure all patients pay a fair price at the pharmacy counter.

Peter J. Pitts, a former Food and Drug Administration associate commissioner, is president of the Center for Medicine in the Public Interest.

The viewpoints expressed above are those of the author and do not necessarily reflect those of The Independent.

How to submit an article, guest opinion piece, or letter to the editor to The Independent

Do you have something to say? Want your voice to be heard by thousands of readers? Send The Independent your letter to the editor or guest opinion piece. All submissions will be considered for publication by our editorial staff. If your letter or editorial is accepted, it will run on suindependent.com, and we’ll promote it through all of our social media channels. We may even decide to include it in our monthly print edition. Just follow our simple submission guidelines and make your voice heard:

—Submissions should be between 300 and 1,500 words.

—Submissions must be sent to editor@infowest.com as a .doc, .docx, .txt, or .rtf file.

—The subject line of the email containing your submission should read “Letter to the editor.”

—Attach your name to both the email and the document file (we don’t run anonymous letters).

—If you have a photo or image you’d like us to use and it’s in .jpg format, at least 1200 X 754 pixels large, and your intellectual property (you own the copyright), feel free to attach it as well, though we reserve the right to choose a different image.

—If you are on Twitter and would like a shout-out when your piece or letter is published, include that in your correspondence and we’ll give you a mention at the time of publication.

Articles related to “HHS Secretary Azar’s drug price plan is a gift to global ‘freeloaders'”

Azar’s crackdown on foreign freeloading misses the mark

Don’t import foreign price controls — break them

The International Price Index would be terrible for health care

Click This Ad

LEAVE A REPLY

Please enter your comment!
Please enter your name here